Dr. Gregory A. Durm, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 120
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IN license 01070705A -
Internal Medicine Physician
IN license 01070705A -
Medical Oncology Physician
IN license 01070705A - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
- Indiana University Health Bloomington Hospital Bloomington, IN
- Indiana University Health Ball Memorial Hospital Muncie, IN
- Indiana University Health North Hospital Carmel, IN
- Iu Health West Hospital Avon, IN
Medical groups
- Iu Health Medical Group LLC (4,462 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 120
- Services billed
- 362
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 171 | 59 |
| Established patient office or other outpatient visit, 20-29 minutes | 39 | 34 |
| Established patient office or other outpatient visit, 40-54 minutes | 25 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | 17 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Indianapolis, IN | 58 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Indianapolis, IN | 50 |
| Prochlorperazine Maleate Other prescribers in Indianapolis, IN | 40 |
| Ondansetron Odt (ondansetron) Other prescribers in Indianapolis, IN | 39 |
| Prednisone Other prescribers in Indianapolis, IN | 34 |
| Eliquis (apixaban) Other prescribers in Indianapolis, IN | 34 |
| Retevmo (selpercatinib) | 34 |
| Gabapentin Other prescribers in Indianapolis, IN | 32 |
| Ondansetron Hcl Other prescribers in Indianapolis, IN | 32 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Indianapolis, IN | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $119 in total to this clinician.
| Genentech, Inc. | $76.27 |
|---|---|
| Amgen Inc. | $25.43 |
| Regeneron Healthcare Solutions, Inc. | $17.02 |
| Food and Beverage | $102 |
|---|---|
| Education | $17.02 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Jan 6, 2025 | Education LIBTAYO · ONCOLOGY · in-kind | $17.02 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 8 companies. The companies reported $2,337,725 in research payments for these studies, mostly to the institutions running them.
- STUDY NAME# A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer NSCLC with primary tumors between 1-4 cm# Big Ten Cancer Researc…
Merck Sharp & Dohme LLC - STUDY NAME#A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer NSCLC with primary tumors between 1-4 cm# Big Ten Cancer Research…
Merck Sharp & Dohme LLC - A Phase II study of Concurrent Chemoradiation plus Durvalumab (MEDI4736) followed by Surgery followed by Adjuvant Duralumab (Medi4736) in medically operable patients with surgically resectable Stage IIIA (N2) Non Smal…
AstraZeneca Pharmaceuticals LP - STUDY NAME#A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer NSCLC with primary tumors between 1-4 cm
Merck Sharp & Dohme LLC - A Phase 1 Open Label Multiple Dose Dose Escalation and Expansion Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients Wit…
Day One Biopharmaceuticals - Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company · Active, not recruiting · NCT04956640 - A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company · Active, not recruiting · NCT06607185 - A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company · Recruiting · NCT06119581 - An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or meta…
Boehringer Ingelheim International GmbH - A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.